3 ottobre 2023 – Walder Wyss has advised co-led investors Swisscanto and imec.xpand in connection with Nagi Bioscience’s Series A Financing round in the amount of CHF 12.4m. Nagi Bioscience is a Swiss life sciences company developing next-generation laboratory equipment to unlock the full potential of alternatives to animal testing. Swisscanto is the asset management arm of the Zürcher Kantonalbank, one of Switzerland’s largest fund providers, developing high-quality investment and pension solutions for private investors, companies and institutions. imec.xpand is an early stage and growth venture capital fund with a game-changing approach to turn hardware driven nanotechnology innovation into successful global companies.

The Walder Wyss team was led by Alexandre Both (Partner, Corporate/M&A) and included Sébastien Aubert (Associate, Corporate/M&A) and Alexander Sorton (Senior Associate, Corporate/M&A).